New research highlights the immune-activating potential of Aliya PEF Energy, augmenting its use in oncology and chronic lung disease treatments.

Galvanize Therapeutics has successfully completed its inaugural commercial procedures using the FDA-cleared Aliya EX System, enhancing patient treatment options.

Galvanize Therapeutics has received FDA clearance for its Aliya EX Generator, significantly advancing soft tissue surgical ablation techniques and expanding treatment options.

Galvanize Therapeutics has appointed Laura Francis, experienced in the medical technology space, to its Board of Directors to enhance company leadership.

Recent findings from a clinical study reveal that Aliya® Pulsed Electric Field Ablation effectively controls lung tumors and may enhance immune responses in patients with advanced cancer.

Galvanize Therapeutics has raised $100 million in Series C funding, aiming to revolutionize treatments for cancer and chronic lung disease with its unique PEF technology.

Galvanize Therapeutics has enrolled its first patient in the PROPEL Registry, a significant step in assessing Aliya® PEF ablation's efficacy for soft tissue lesions.